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AMP-activatedproteinkinase (AMPK) isactivated inadipocytes
during exercise and other states in which lipolysis is stimulated.
However, themechanism(s) responsible for this effect and itsphys-
iological relevance are unclear. To examine these questions,
3T3-L1 adipocytes were treated with cAMP-inducing agents (iso-
proterenol, forskolin, and isobutylmethylxanthine), which stimu-
late lipolysis and activate AMPK. When lipolysis was partially
inhibited with the general lipase inhibitor orlistat, AMPK activa-
tion by these agentswas also partially reduced, but the increases in
cAMP levels and cAMP-dependent protein kinase (PKA) activity
were unaffected. Likewise, small hairpin RNA-mediated silencing
of adipose tissue triglyceride lipase inhibited both forskolin-stim-
ulated lipolysis andAMPKactivation but not that of PKA. Forsko-
lin treatment increased the AMP:ATP ratio, and this too was
reduced by orlistat. When acyl-CoA synthetase, which catalyzes
the conversion of fatty acids to fatty acyl-CoA, was inhibited with
triacsinC, the increases inbothAMPKactivityandAMP:ATPratio
wereblunted. Isoproterenol-stimulated lipolysiswas accompanied
by an increase in oxidative stress, an effect that was quintupled in
cells incubatedwith theAMPKinhibitorcompoundC.The isopro-
terenol-induced increase in the AMP:ATP ratio was also much
greater in these cells. In conclusion, the results indicate that activa-
tion of AMPK in adipocytes by cAMP-inducing agents is a conse-
quence of lipolysis and not of PKA activation. They suggest that
AMPK activation in this setting is caused by an increase in the
AMP:ATP ratio that appears to be due, at least in part, to the acy-
lation of fatty acids. Finally, this AMPK activation appears to
restrain the energy depletion and oxidative stress caused by
lipolysis.
AMP-activated protein kinase (AMPK)2 is a sensor of cellu-
lar energy state that responds to metabolic stresses and other
regulatory signals. The mechanism of activation of AMPK is a
complex phenomenon and is still not fully understood,
although it is recognized that it involves phosphorylation of the
critical Thr-172 residue of its  catalytic subunit by upstream
kinases such as LKB1, Ca2-calmodulin-dependent protein
kinase kinase, and possibly Tak1, a member of the mitogen-
activated protein kinase kinase kinase family (1–5). AMPK is
also regulated byAMP allosterically and the current view is that
this both increases AMPK activity directly and makes it a
poorer substrate for phosphatases (6).
The role and regulation of AMPK in muscle, liver, and vari-
ous cultured cells have been extensively studied. It is now well
established that energy depletion because of starvation,
hypoxia, and exercise increases the intracellular AMP:ATP
ratio and secondarily AMPK activity (7). Upon its activation, a
major role of AMPK is to replete cellular energy stores by stim-
ulating processes that generate ATP, such as fatty acid oxida-
tion, and inhibiting ATP-consuming pathways (e.g. lipogenesis,
triglyceride synthesis, and gluconeogenesis) that are not acutely
needed for cell survival (7). In addition, changes in the levels of
various hormones and fuels have been demonstrated to activate
or inhibit AMPK suggesting that its regulation and physiologi-
cal relevance are more complex than initially appreciated. In
keepingwith this notion, AMPKhas also been shown to protect
cells by reducing or even preventing a variety of stress
responses, including the generation of free radicals and inflam-
mation (8–12).
Adipose tissue is a key player in whole-body energy regula-
tion. One of itsmajor roles is to provide free fatty acids (FFA) as
a fuel for other tissues in times of need. In these circumstances,
catecholamines, and possibly other hormones and neurotrans-
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mitters, rapidly activate-adrenergic receptors and the cAMP-
dependent protein kinase (PKA) axis. This results in the stim-
ulation of lipolysis by a complex regulatory mechanism that
appears to involve hormone-sensitive lipase, adipose-tissue
triglyceride lipase (ATGL), and perilipin, a lipid droplet-associ-
ated phosphoprotein that has proven to be essential for -ad-
renergic stimulation of lipolysis (13–17). In recent years, ATGL
has been identified as the predominant lipase responsible for
the initial step in hydrolyzing triglycerides, at least in rodents
(18–20).
Despite its prominent role in energy metabolism, few inves-
tigations have addressed the regulation of AMPK in adipose
tissue. Previous studies conducted in our laboratory first
showed that in rodents exercise increases AMPK activity in
intra-abdominal adipose tissue (21, 22). Acute exercise is
known to increase the release of catecholamines, which partic-
ipate in the lipolytic response of adipose tissue to exercise. In
keeping with this notion, -adrenergic agonists and agents that
increase cAMP have been found to stimulate both lipolysis and
AMPK activation in cultured adipocytes (23, 24), and to cause a
decrease in their cellular energy state in vitro (25–28) and in
rats in vivo (29). Despite this, the mechanism(s) by which these
agents activate AMPK, and whether it is dependent on their
ability to stimulate lipolysis is unknown, as is the physiological
significance of AMPK activation in this setting. To address
these questions, we first examined activation of AMPK by
agents that increase cAMP in cultured adipocytes in situations
in which their ability to stimulate lipolysis was inhibited down-
stream of PKA. We then investigated the consequences of
inhibiting AMPK activation on reactive oxygen species (ROS)
generation and energy depletion in these cells.
EXPERIMENTAL PROCEDURES
Culture of 3T3-L1 Adipocytes—3T3-L1 preadipocytes were
purchased fromAmerican Type Culture Collection (Manassas,
VA). 3T3-L1 preadipocytes placed in 12-well plates were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10% bovine calf serum and differentiated to adipocytes
using standard protocols (30). 3T3-L1 attained a fully differen-
tiated state on day 10 after the initiation of the differentiation
protocol, and experiments were done on days 12–16. DMEM,
bovine calf serum, and fetal bovine serumwere purchased from
Invitrogen.
Generation and Differentiation of Stable Lines of Peri/
Mouse Embryonic Fibroblast Adipocytes—Stable lines of MEFs
were generated fromembryos of perilipin nullmice (Peri/) as
described previously (13, 14, 31). MEF adipocytes were gener-
ated by retroviral expression of peroxisome proliferator-acti-
vated receptor- (31) followed by selection, expansion, and dif-
ferentiation using a standard differentiation medium (13, 14).
MEFs attained a differentiated adipocyte phenotype within 7
days of culturing in differentiation medium (13, 14).
Adenoviral Expression of GFP and Peri A Constructs in
Peri/ MEF Adipocytes—Adenoviruses expressing Aequoria
victoria green fluorescent protein (Ad-GFP) or wild-type per-
ilipin A (Ad-WT Peri A) were generated and verified as
described previously (13, 14, 32). Recombinant adenovirus was
transduced into Peri/ MEFs with Lipofectamine PlusTM
(Invitrogen) on day 3 after induction of differentiation. The
amount of each adenovirus used was selected to ensure compa-
rable levels of expression of the different Peri A constructs,
which was confirmed by Western blots and densitometry (13,
14, 32). GFP was transduced in Peri/ MEFs as a negative
control.
Recombinant Adenoviruses Expressing Small Hairpin RNA
(shRNA) Directed Against Murine ATGL—ATGL shRNA
designwas based onGenBankTMaccession numberNM025802
(sequence GGAGAGAACGTCATCATAT) as described (13).
A “scrambled” version of these shRNA (CGCGCTTTGTAG-
GATTCA) was generated as a control for nonspecific effects of
shRNA. All shRNAs were cloned into the pQuiet vector to gen-
erate recombinant adenoviruses. Recombinant adenovirus
expressing shRNAs was transduced into MEFs cells with Lipo-
fectamine PlusTM on day 2 after induction of differentiation.
Lipolysis Assays—Lipolysis was stimulated by addition of the
-adrenergic agonist isoproterenol (10 M), the adenylate
cyclase activator forskolin (20 M), or the phosphodiesterase
inhibitor isobutylmethylxanthine (IBMX) (0.5mM) into serum-
free culture medium containing 0.5% fatty acid-free bovine
serum albumin (Celliance, Toronto, Canada) in the presence or
absence of the general lipase inhibitor orlistat (100 M), the
ACS inhibitor triacsin C (6 M), or the AMPK inhibitor com-
pound C (50 M). Lipolysis was assessed from the release of
glycerol and FFA in the culturemedium as described previously
(14) using free glycerol reagent (Sigma) and nonesterified fatty
acids measurement kit (Waco Diagnostics, Richmond, VA).
Triacsin C was purchased from Biomol (Plymouth Meeting,
PA), compound C from Calbiochem, and other compounds
from Sigma.
Immunoblot Analysis—Cultured cells were scraped on ice in
cell lysis buffer (plus 1mMphenylmethylsulfonyl fluoride), son-
icated, and centrifuged (14,000 g for 15 min at 4 °C). Protein
concentrations of cell supernatants were determined using the
bicinchoninic acid (BCA) reagents (Pierce) using bovine serum
albumin as the standard. Proteins (20 g) were separated by
SDS-PAGE and transferred to polyvinylidene difluoride mem-
branes (Amersham Biosciences). Membranes were blocked in
Tris-buffered saline (pH 7.5) containing 0.05% Tween 20
(TBST) and 5% milk for 1 h at room temperature and then
probed with antibodies specific to -actin, perilipin, or ATGL
for 1 h at room temperature, or specific to P-AMPK Thr-172,
pan-AMPK, P-ACC Ser-79, P-LKB1 Ser-431, P-CREB Ser-
133, phospho-(Ser/Thr)-PKA substrate overnight at 4 °C.
Bound antibodieswere detectedwith the appropriate horserad-
ish peroxidase-linked whole secondary antibodies. Protein
immunoblots were visualized by enhanced chemiluminescence,
and bands were quantified with scanning densitometry. Antibod-
ies for pan--AMPK, P-AMPK Thr-172, and P-CREB Ser-133,
phospho-(Ser/Thr)-PKA substrate, and cell lysis buffer were pur-
chased from Cell Signaling Technology (Beverly, MA); P-ACC
Ser-79 was from Upstate Biotechnology, Inc. (Lake Placid, NY);
-actin was from Sigma; P-LKB1 Ser-431 and mouse and rabbit
antibodies conjugated to horseradish peroxidase were obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Specific
polyclonal ant-rabbit ATGL and perilipin antibody were gener-
ated and affinity-purified as described (13–15).
AMPK Is Activated by Lipolysis and Protects the Adipocyte
JUNE 13, 2008•VOLUME 283•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 16515
 at H
O
K
K
A
ID
O
 D
A
IG
A
K
U
 on O
ctober 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Determination of AMPK Activity—3T3-L1 express mainly
the 1 isoform of AMPK (data not shown and see Ref. 33).
AMPK 1 activity was measured after 1 h of treatment with or
without isoproterenol (10 M) in 3T3-L1 adipocytes. In addi-
tion, a possible nonspecific direct effect of orlistat or triacsin C
onAMPKactivitywas ruled out bymeasuringAMPKactivity in
a cell-free system with/without the presence of orlistat (100
M) or triacsin C (6 M). To do so, untreated 3T3-L1 lysates
containing 100 g of protein were immunoprecipitated with
AMPK1-specific polyclonal antibody (Bethyl Laboratories
Inc., Montgomery, TX) and protein A/G-agarose beads. Beads
were washed, and the immobilized enzyme was assayed based
on the phosphorylation of SAMS peptide (HMRSAMS-
GLHLVKRR) (0.2 mmol/liter) by 0.2mmol/liter ATP (contain-
ing 2 Ci of [-32P]ATP) in the presence and absence of 0.2
mmol/liter AMP and the presence or absence of orlistat (100
M) or triacsin C (6 M). Label incorporation into the SAMS
peptide was measured using a scintillation counter.
Nucleotide Studies in 3T3-L1 Adipocytes—Cellular levels of
ATP, ADP, and AMP were measured spectrophotometrically as
described previously (34, 35). In brief, 3T3-L1 adipocytes were
treated asdescribedunder “LipolysisAssays.”After the incubation
period, the media were kept for glycerol measurements, and the
cells were washed once with cold phosphate-buffered saline, and
proteins were precipitated with 1% trichloroacetic acid. The acid
was then removed from the aqueous phase of the trichloroacetic
acid extracts with repeated washes with ether. The samples were
then dried to powder and kept at80 °C until the assay.
Determination of Intracellular cAMP Content in 3T3-L1
Adipocytes—3T3-L1 adipocytes were treated as described
under “Lipolysis Assays.” After the incubation period, cAMP
was extracted and measured using a commercially available
cAMP EIA kit according to the instructions provided by the
manufacturer (Biomedical Technologies Inc., Stoughton, MA).
Detection of Reactive Oxygen Species—3T3-L1 adipocytes
were incubated overnight with compound C or vehicle
(DMSO) and thereafter treated for 1 h with isoproterenol and
loaded with the redox-sensitive dye 5-(and-6)-chloromethyl-
2,7-dichlorodihydrofluorescein diacetate (DCF, Invitrogen)
during the last 30 min of this incubation period. After the load-
ing period, the media were kept for glycerol assay, and cells
were washed with and incubated in pre-warmed Hanks’ buff-
ered saline solution at 37 °C. Reactive oxygen species (H2O2 and
OH) formation was measured for 1 h in a multiwell fluores-
cence plate reader (FluoroskanAscent, Labsystems) set at 37 °C
using excitation and emission filters of 485 and 538 nm, respec-
tively. At the end of the DCF experiment, tert-butyl hydroper-
oxide (1 mM) (Sigma) was added to the incubation media to
verify that the measurement maximal capacity of the system
had not been reached during the experiment.
Statistical Analysis—Results were analyzed using Statview
version 5.0.1 and are presented as means S.E. of at least three
independent experiments. Statistical significance was deter-
mined by a one-way or two-way analysis of variance for nonre-
peated or repeatedmeasures, as appropriate. Fisher’s protected
least significant difference post hoc test was used in the event of
a significant (p 0.05) ratio.
RESULTS
Agents That Increase cAMP Stimulate Both Lipolysis and
AMPK Activation in Adipocytes—Incubation of 3T3-L1 adipo-
cytes with a -adrenergic agonist (isoproterenol, 10M) and an
adenylyl cyclase activator (forskolin, 20 M) caused a 20-fold
increase in lipolysis (Fig. 1B). In confirmation of previous
reports (23, 24), these agents also activated AMPK as reflected
by increases in the phosphorylation of its -subunit at Thr-172
and of its downstream target ACC at Ser-79 (Fig. 1A). That
isoproterenol activates AMPK was confirmed by measure-
ments of the activity of AMPK 1, the main isoform expressed
in 3T3-L1 adipocytes (data not shown). Incubation of the cells
with the phosphodiesterase inhibitor IBMX (0.5mM) also stim-
ulated lipolysis and increased AMPK and ACC phosphoryla-
tion (Fig. 1, A and B). Because the phosphodiesterase catalyzes
the conversion of cAMP to AMP, this essentially rules out this
source of AMP as a major cause of AMPK activation during
lipolysis.
Iinhibition of Lipolysis by Orlistat Reduces AMPK Activation
by Agents That Increase cAMP—We next sought to determine
whether AMPK activation by isoproterenol, forskolin, and
IBMX is related to their ability to stimulate lipolysis. To test this
possibility, we incubated adipocytes with orlistat, a general
lipase inhibitor (36). As shown in Fig. 2, orlistat inhibited the
ability of all three lipolytic agents to stimulate lipolysis by50%
(Fig. 2,A and B), and it had a similar inhibitory effect on AMPK
FIGURE1.Agonists that increasecAMPstimulateboth lipolysisandAMPK
activation. L1 adipocyteswere treatedwith the phosphodiesterase inhibitor
IBMX (0.5mM), the-agonist isoproterenol (Iso, 10M), or the adenylyl cyclase
activator forskolin (FKN, 20M) for 1h, followinga4-hpreincubationperiod in
serum-free DMEM containing 0.5% fatty acid-free BSA. Ctrl, control. A, activa-
tion of AMPK as assessed from immunoblots of phospho-AMPK Thr-172 and
P-ACC Ser-79. IB, immunoblot. B, lipolysis was quantified on the basis of glyc-
erol release into the incubation media. Results for glycerol release are
means S.E. (n 9) and were obtained in three independent experiments.
Immunoblots shown are representative of those obtained in a total of nine
lysates. Significantly different from control group: ***, p 0.001.
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activation (Fig. 2, C–E). The possibility that orlistat could have
a direct inhibitory action on AMPK was ruled out by its lack of
effect on AMPK activity in a cell-free system (data not shown, see
under “Experimental Procedures”). Regression analyses revealed a
strong positive correlation between both P-AMPK Thr-172 and
lipolysis (r2 0.44; p 0.0001) and between P-ACC Ser-79 and
lipolysis (r2 0.64; p 0.0001) (Fig. 3,A and B).
Inhibition of Stimulated Lipolysis by Orlistat Does Not Alter
cAMP or PKA Signaling—Forskolin, the only agent tested,
caused a 50-fold increase in intracellular cAMP levels (Fig. 4A).
Likewise, the three lipolytic agents augmented PKA activity as
reflected by their ability to increase the abundance of phospho-
rylated serine and threonine residues of PKA substrates (P-
PKA substrate) (Fig. 4B). The most
abundant P-PKA substrate was
found at 62 kDa (Fig. 4B), which
corresponds to the molecular
weight of perilipin, the predomi-
nant PKA substrate in adipocytes
(17, 37). These agents also increased
the phosphorylation of Ser-133 on
the cAMP-response element-binding
protein (CREB)andSer-431onLKB1,
twodownstreamtargetsofcAMPand
PKA (38–40) (Fig. 4, B, E and F).
Treatment with orlistat did not affect
any of these events (Fig. 4,A–C, E and
F), indicating that it inhibited lipolysis
downstream of cAMP and PKA. Col-
lectively, the data suggest that the
activation of AMPK by agents that
increase cAMP in adipocytes is the
result of increased lipolysis and that it
is not a direct effect of cAMP or PKA
activation.
Inhibition of Stimulated Lipolysis
by GeneticMeans Abrogates Forsko-
lin-induced AMPK Activation—To
examine further the relationship
between lipolysis andAMPK activa-
tion, we next used genetic
approaches to inhibit or restore for-
skolin-stimulated lipolysis down-
streamof PKA. For this purpose cul-
tured adipocytes derived from
MEFs of Peri/mice were utilized
because such cells exhibit a robust
reduction in forskolin-stimulated
lipolysis despite normal PKA activa-
tion (13, 14), in keeping with the
observation that perilipin is essen-
tial for PKA-mediated lipolysis (15–
17). In addition, we have found that
the adenoviral expression of wild-
type perilipin A restores forskolin-
stimulated lipolysis in these adipo-
cytes and that shRNA-mediated
silencing of ATGL reverses this effect
(13, 14). Finally, these cells exhibit the biochemical and physiolog-
ical hallmarks of true adipocytes and that they be more easily
infected with adenoviruses than 3T3-L1 adipocytes (13, 14).
In agreement with our previous reports (13, 14), the stimu-
lation of lipolysis (glycerol release) by forskolin was only 3-fold
in the Peri/MEF adipocytes infected with Ad-GFP as a neg-
ative control, whereas in adipocytes infected with wild-type
perilipin A glycerol release was increased by 26-fold (Fig. 5A).
Similar changes were found for the release of FFA (Fig. 5B).
Transduction of the cells with an ATGL-directed shRNA led to
the near total abrogation of forskolin-stimulated glycerol and
FFA release both in the peri-null and in the MEF adipocytes
expressingWTperilipin A (Fig. 5,A and B). In keeping with the
FIGURE2. Inhibitionof lipolysiswith thegeneral lipase inhibitororlistatblunts theactivationofAMPKby
agents that increase cAMP. 3T3-L1 adipocytes were treatedwith IBMX (0.5mM), isoproterenol (Iso, 10M), or
forskolin (20 M) for 1 h, following a 4-h preincubation period in serum-free DMEM containing 0.5% fatty
acid-free BSAwith/without orlistat (100M). Lipolysis was assessed bymeasuring the release of glycerol (A) or
FFA (B) into the incubation media and the activation of AMPK by immunoblots (IB) of phospho-AMPK and
phospho-ACC (C) as described in the legend of Fig. 1. Densitometric analyses of P-AMPK (D) and P-ACC (E) are
shown. N.D., nondetectable. Immunoblots shown are representative of nine samples obtained in three inde-
pendent experiments. Results in A, B, D, and E are expressed as means S.E. (n 9) and were obtained from
three independent experiments. Significantly different from control group: *, p 0.05; **, p 0.01; ***, p
0.001; significantly different from orlistat-treated cells:, p 0.01;, p 0.001.
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results obtained with orlistat in
3T3-L1 adipocytes, the very weak
forskolin-induced stimulation of
lipolysis in the peri-null adipo-
cytes was not accompanied by
AMPK phosphorylation (Fig. 5,
A–D). In contrast, the adenoviral
expression of WT Peri A led to the
robust restoration of both forsko-
lin-induced lipolysis and AMPK
phosphorylation (Fig. 5, A–D). Con-
versely, shRNA-mediated silencing
of ATGL in these cells reversed
both forskolin-induced lipolysis
and AMPK phosphorylation (Fig.
5, A–D).
Immunoblots demonstrated that
the adenoviral expression of Peri A
was successful (Fig. 5C). Accord-
ingly, Peri/ MEF adipocytes
(GFP) were characterized by the
absence of perilipin (Fig. 5C, lanes
1–4), whereas the adipocytes trans-
duced with wild-type Peri A (WT
Peri A; Fig. 5C, lanes 5–8) expressed
perilipin. ATGLwas present in both
of these cells, and its expression was
reduced by 100% as a result of
transduction of an shRNA directed
against ATGL (Fig. 5C). None of the
genetic maneuvers significantly
affected the abundance of AMPK
(Fig. 5, C and E). For reasons
unknown, in experiments carried
out with the MEF adipocytes, the
phosphorylation of ACC Ser-79 was
not changed by forskolin treatment
as it was in the 3T3-L1 adipocytes
(data not shown). Notwithstanding
this discrepancy, these results sup-
port the notion that in adipocytes
the activation of AMPK by agents
that induce cAMP is a consequence
of the stimulation of lipolysis.
Inhibition of Stimulated Lipoly-
sis by shRNA-mediated Silencing
of ATGL Does Not Alter PKA
Signaling—Forskolin treatment in-
creased the abundance of phos-
phorylated serine and threonine
residues of PKA substrates (P-
PKA substrate) both in the perilipin
null and in the MEF adipocytes
expressing perilipin A (Fig. 5C).
This phosphorylation event was not
affected by the ATGL-directed
shRNA suggesting PKA activity was
not altered (Fig. 5C). The major
FIGURE 3.Correlation ofmeasures of AMPKactivation and lipolysis in adipocytes stimulatedby agents that
increase cAMP. Lipolysis was assessed on the basis of glycerol release and was correlated with the abundance of
P-AMPK Thr-172 (A) and P-ACC Ser-79 (B). Individual valueswere obtained in the experiments described in Fig. 2.
FIGURE 4.Orlistat inhibits AMPK activationwithout affecting cAMP levels and PKA signaling. A, intracel-
lular levels of cAMP in 3T3-L1 adipocytes treated with forskolin with/without orlistat as described in Fig. 2.
B, cell lysates obtained in the experiment described in Fig. 2 were immunoblotted (IB) with antibodies recog-
nizingphosphorylated serineand threonine residuesof PKAsubstrates (P-PKA), total-AMPK, thePKAdown-
stream targets P-LKB1 Ser-431, P-CREB Ser-133, and -actin. Densitometric analyses are as follows: C, P-PKA
substrate62 kDa; D, -AMPK; E, P-LKB1 Ser-431; and F, P-CREB Ser-133. Immunoblots shown are represent-
ative of nine samples obtained in three independent experiments. Results in A, C, D, E, and F are expressed as
means S.E. (n 9). Significantly different from control group: ***, p 0.001. Iso, isoproterenol.
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P-PKA substrates were found at
84 and 62 kDa, which corre-
sponds, respectively, to the molecu-
lar weight of hormone-sensitive
lipase, a known PKA substrate, and
perilipin, the predominant PKA
substrate in adipocytes (17, 37). The
light P-PKA substrate band found at
62 kDa in the perilipin null adipo-
cytes suggests the presence of
another PKA substrate whose iden-
tity has yet to be determined. Fors-
kolin treatment of the MEF adipo-
cytes expressing WT Peri A led to
the hyperphosphorylation of perili-
pin (17), as suggested by its higher
migration in the immunoblotted
samples (Fig. 5C). That hyperphos-
phorylation of perilipin was not
affected by transduction of the
ATGL shRNA indicates that PKA
activity was not altered by this
genetic manipulation.
Effect of Stimulating and Inhib-
iting Lipolysis on the Concentra-
tion of Adenine Nucleotides—Be-
cause AMPK activity is known to
be modulated by changes in the
energy state of cells, we next eval-
uated the effect of stimulating and
inhibiting lipolysis on cellular lev-
els of ATP, ADP, and AMP in
3T3-L1 adipocytes. As shown in
Table 1, forskolin caused an25%
decrease in ATP levels, no signifi-
cant change in ADP, and an 2.8-
fold increase in AMP, resulting in
an 4-fold increase in the AMP:
ATP ratio compared with control
cells. Orlistat treatment, which
partially inhibited lipolysis and
AMPK activation (Fig. 2), also
markedly reduced the increase in
the AMP:ATP ratio caused by for-
skolin, although not to control val-
ues. Neither the lipolytic agents,
nor orlistat, nor the genetic
FIGURE 5. The absence of perilipin or the shRNA-mediated silencing of ATGL inhibit both forskolin-
stimulated lipolysis and AMPK activation in Peri/MEF adipocytes. Adipocytes retrovirally engineered
from murine embryonic fibroblasts of perilipin null mice (Peri/MEFs) were transduced with an adenovirus
expressing GFP (negative control) or wild-type perilipin A (WT Peri A) and with either an ATGL-directed shRNA
or a scrambled shRNA. After differentiation to adipocytes, cells were serum-depleted in DMEM containing 2%
fatty acid-free BSA and treated for 2 h with/without forskolin. A,medium glycerol; B,medium FFA. Represent-
ative immunoblots of phosphorylated serine and threonine residues of PKA substrates (P-PKA), perilipin,
ATGL, P-AMPK Thr-172,-AMPK, and-actin (C). Densitometric analysis of P-AMPK Thr-172 (D) and-AMPK (E)
immunoblots. Results in A and B are expressed as means S.E. (n 9) obtained in three independent exper-
iments. Significantly different from basal control group: *, p 0.05, ***, p 0.001. IB, immunoblot.
TABLE 1
Cellular adenine nucleotide levels in 3T3-L1 adipocytes
Data are expressed as means S.E. (n 5) and were obtained in four independent experiments.
ATP ADP AMP AMP/ATP
nmol/mg protein nmol/mg protein nmol/mg protein
Control 11.39 0.83 3.72 0.81 0.38 0.04 0.034 0.004
Control orlistat 12.91 0.73 4.23 0.82 0.4 0.03 0.031 0.001
Forskolin 8.39 0.59a 5.19 0.89 1.06 0.14b 0.130 0.023b
Forskolin orlistat 9.15 1.14a 4.64 1.03 0.68 0.11a,c 0.074 0.009a,c
a Significantly different from control counterpart, p 0.05.
b Significantly different from control counterpart, p 0.001.
c Significantly different from the group treated with forskolin alone, p 0.01.
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manipulations affected the abundance of the -AMPK sub-
unit (Fig. 4, B and D, and Fig. 5, C and E).
Effect of the Inhibition of Acyl-CoA Synthetase on Cellular
Energy State and AMPK Activation—A portion of the FFA
released during lipolysis in the adipocyte can be converted to
fatty acyl-CoA by an energy-consuming reaction catalyzed by
acyl-CoA synthetase (ACS, EC 6.2.1.3) in which ATP is con-
sumed and AMP is generated (Fig. 6A). To test whether this
reaction is relevant for the energy depletion that occurs when
lipolysis is stimulated, differentiated 3T3-L1 adipocytes were
incubated with isoproterenol in the presence or absence of the
ACS inhibitor triacsin C (41–43). Isoproterenol, like forskolin
(Table 1), caused a 5-fold increase in the cellular AMP:ATP
ratio (Fig. 6E) as a result of both a decrease in ATP and an
increase in AMP (data not shown).
Co-incubation with triacsin C, a
concentration (6 M) previously
shown to inhibitACS in 3T3-L1 adi-
pocytes (41), blunted the isoproter-
enol-induced increases in both the
AMP:ATP ratio and the abundance
of P-AMPK and P-ACC (Fig. 6,
B–E). In contrast, triacsin C treat-
ment had no effect on lipolysis in
intact cells (Fig. 6F). The possibility
that triacsin C could have a direct
inhibitory action on AMPK was
ruled out by its lack of effect on
AMPK activity in a cell-free system
(data not shown, see “Experimental
Procedures”). Collectively, these
data suggest that the acylation of
FFAs by ACS plays a role in lipoly-
sis-induced decrease in energy state
and AMPK activation.
Effect of the Inhibition of AMPK
by Compound C on ROS Generation
in the Presence and Absence of
Isoproterenol—Exogenous FFAs
have been shown to increase ROS
generation in 3T3-L1 adipocytes
(44, 45). We observed a similar phe-
nomenon when cellular FFAs were
increased by stimulating lipolysis.
Thus, isoproterenol treatment of
3T3-L1 adipocytes for 1 h led to a
25% increase in ROS generation, as
measured by DCF fluorescence
(0.757  0.24 versus 0.606  0.24
arbitrary fluorescence units in con-
trol cells; p  0.05). AMPK activa-
tion has been found to reduce ROS
generation in endothelial cells (10,
46). To assess if decreased AMPK
activity has the opposite effect,
3T3-L1 adipocytes were incubated
with the competitive inhibitor of
AMPK compound C (29, 47). As
shown in Fig. 7A, a 20-h incubation with 20–80 M CC
increased ROS production in 3T3-L1 adipocytes in a dose-de-
pendentmanner (p 0.05 between each concentration and the
one that precedes it). Lower concentrations of CC had no effect
(data not shown). Most impressively, 1 h of isoproterenol stim-
ulation in the presence of 50 M CC resulted in a further 5-fold
increase in ROS production (p  0.001) (Fig. 7B). In these
experiments, preincubation of the cells with CC for 20 h
increased their basal rate of lipolysis; however, it did not impair
the ability of isoproterenol to stimulate glycerol release (Fig.
7C). Treatment of the cells with 50 M compound C for 20 h
decreased both basal and isoproterenol-stimulated AMPK
activity as reflected by the phosphorylation of AMPK Thr-172
and ACC Ser-79 (Fig. 7D).
FIGURE 6. Treatment with the acyl-CoA synthetase inhibitor triacsin C blunts the increases in both the
cellular AMP:ATP ratio and AMPK activity when lipolysis is stimulated by isoproterenol. Stimulation of
lipolysis releases intracellular fatty acids that can be either released into themedia or, as shown in A, activated
byACS to form fatty acyl-CoA in a reaction that consumesATP andproduces AMP; triacsin C is anACS inhibitor.
3T3-L1 adipocytes were preincubated for 4 h in serum-free DMEM containing 2% fatty acid-free BSA and then
incubatedwith triacsinC (6M) or vehicle (DMSO) for 30minprior to the additionof isoproterenol for 1 h.B, cell
extracts were immunoblotted (IB) for P-ACC Ser-79, P-AMPK Thr-172, and -actin. Densitometric analyses of
immunoblots for P-AMPK (C) andP-ACC (D) are shown. E, cellularAMP toATP ratio. F, lipolysiswasquantifiedon
the basis of glycerol release into themedium. Immunoblots shown are representative of three separate exper-
iments performed in duplicate. Results are expressed as mean  S.E. (n  6) and were obtained in three
independent experiments. Significantly different from control group, *, p 0.05; **, p 0.01;***, p 0.001;
significantly different from vehicle group,, p 0.05; p 0.01.
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Effect of the Inhibition of AMPK
by Compound C on Adenine Nucle-
otides Levels—As shown in Fig. 8,
incubation of the cells with com-
pound C (50 M) for 20 h led to a
2-fold increase in their AMP:ATP
ratio. This was the result of a signif-
icant decrease in ATP as well as
increase in AMP levels (data not
shown). These effects were substan-
tially magnified when the adipo-
cytes were subsequently incubated
for an additional hour with isoprot-
erenol (Fig. 8).
DISCUSSION
We investigated the mechanism
and the physiological relevance of
AMPK activation by agents that
increase cAMP in cultured adipo-
cytes. The major findings are as fol-
lows. 1) AMPK activation by these
agents appears to be secondary to an
increase in the AMP:ATP ratio that
accompanies lipolysis. 2) It is not a
direct effect of increases in cAMP lev-
els and PKA activity. 3) This decrease
in energy state appears to be due, at
least in part, to the acylation of the
fatty acids released during lipolysis. 4)
WhenAMPKactivation is prevented,
the stimulation of lipolysis by isopro-
terenol is associated with an even
greater decrease in energy state and
an increase in oxidative stress.
The observation that agents that raise cAMP levels (isoprot-
erenol, forskolin, and IBMX) activate AMPK in cultured adipo-
cytes is in agreement with previous reports (23, 24, 29, 33). A
novel finding was that activation of AMPK by these agents was
the result of enhanced lipolysis. Thus, AMPK activation, like
lipolysis, was blunted by 50% by the general lipase inhibitor
orlistat in 3T3-L1 adipocytes (Fig. 2) and completely in MEF
adipocytes in which lipolysis was inhibited by genetic modifi-
cations (Peri/ or ATGL shRNA) (Fig. 5). Furthermore, the
ability of forskolin to stimulate lipolysis and activateAMPKwas
restored in perilipin-null MEF adipocytes in which wild-type
perilipin A was expressed (Fig. 5). In contrast, inhibition of
lipolysis did not affect cAMP levels or the cAMP-induced
increase in PKA activity, as evidenced by the finding that phos-
phorylation of the downstream targets of PKA, LKB1 Ser-431,
CREB Ser-133, and perilipin were all unchanged. In addition,
neither orlistat nor the ATGL-directed shRNA altered the
abundance of phosphorylated serine and threonine residues of
PKA substrates (Fig. 4, B andC, and Fig. 5C). Thus, increases in
cAMP and PKA activation, in the absence of lipolysis, are insuf-
ficient to cause the observed activation of AMPK.
LKB1 is an AMPK kinase (1, 2). Whether the phosphoryla-
tion of its Ser-431 residue observed in this study contributed to
FIGURE 7. Inhibition of AMPK activity with compound C increases ROS production and lipolysis. 3T3-L1
adipocytes were treated with the AMPK inhibitor CC or vehicle for 20 h. A, dose-response of increases in DCF
fluorescence, a measure of cellular H2O2 and OH content, in response to compound C. B, DCF fluorescence of
adipocytes incubatedwith compoundC (50M) or vehicle for 20 hprior to 1 h stimulation isoproterenol (Iso,
10 M); C, glycerol released into the media; and D, representative immunoblots of P-ACC Ser-79, P-AMPK
Thr-172 and -actin. A.F.U., arbitrary fluorescent units. For A and B, values aremeans S.E. of 2–3 samples in a
representative experiment that was repeated at least three times. For C, values are means S.E. (n 9) and
were obtained in three independent experiments. Significantly different from basal control group, ***, p 
0.001; significant effect of compound C:, p 0.001.
FIGURE 8. Inhibition of AMPK activity with compound C increases both
base-line and isoproterenol-induced changes in AMP:ATP ratio. 3T3-L1
adipocytes were treatedwith compound C (50M) or vehicle for 20 h prior to
1h stimulation isoproterenol (10M). Cellular adeninenucleotides content
wasmeasured as described under the “Experimental Procedures.” Values are
expressed as means S.E. (n 9) and were obtained in three independent
experiments. Significantly different from control group, ***, p 0.001; signif-
icant effect of compound C,, p 0.001.
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the increase in AMPK activity is unclear. Others have found
that the phosphorylation of LKB1 at Ser-431 is essential for the
inhibition of Rat-2 cell growth (39), the regulation of cell polar-
ity inDrosophila (48), and the induction of AMPK phosphoryl-
ation in response to ONOO in HeLa-S3 cells in which LKB1
was knocked in (49). In our system, this phosphorylation event
was insufficient by itself to induce AMPK activation, as evi-
denced by the ability of orlistat to reduce the activation of
AMPK without inhibiting LKB1 Ser-431 phosphorylation (Fig.
4, B and E). Whether the phosphorylation of LKB1 Ser-431 is
necessary for lipolysis-induced AMPK activation remains to be
determined.
The results also suggest that the increase in AMPK caused by
lipolysis is related to a decrease in energy state. In keeping with
this conclusion, AMPK is activated by an increase in the AMP:
ATP ratio (6), and it has long been known that -adrenergic
stimulation of adipocytes is associated with a decrease in ATP
levels (25–28, 50). More recently, this association has been
demonstrated by Goodyear and co-workers (29) who found
that both the AMP:ATP ratio and AMPK activity were
increased in adipose tissue of rats that had been exercised or
injected with epinephrine (29). They also found that these
effects of exercise and epinephrine were prevented by the-ad-
renergic blocker propanolol. The present data suggest that all of
these changes are secondary to the stimulation of lipolysis.
Thus, forskolin-induced increases in both the AMP:ATP ratio
andAMPK activationwere comparably diminishedwhen lipol-
ysis was inhibited by orlistat (Table 1).
Lipolysis by itself is not an energy-consuming metabolic
process. On the other hand, it has been found that about30%
of the FFAs released during fasting is reesterified into triglycer-
ides in rat adipose tissue (51, 52) and as much as 40% in healthy
humans (52, 53). Moreover, in rat adipose tissue in vitro, the
absolute rates of reesterification of FFAs are reported to
increase proportionally with the rate of lipolysis (51, 54, 55).
The reesterification of FFAs requires their acylation, a reaction
catalyzed byACS (EC 6.2.1.3). This reaction both uses ATP and
generates AMP (Fig. 6A); thus two molecules of ATP are
required for every molecule of FFA that is acylated, and a total
of 7–9 ATPs are required for the synthesis of a triglyceride
molecule, depending on the origin of glycerol 3-phosphate. The
energy required for this acylation reaction has been reported to
be the largest single drain of ATP in adipocytes stimulated by
lipolytic hormones (56). The finding in this study that triacsin
C, an ACS inhibitor (41, 43), blunted both the decrease in
energy state and activation of AMPK caused by isoproterenol
supports this conclusion (Fig. 6, B–E). It also suggests that the
acylation of intracellular fatty acids is, at least in part, responsi-
ble for both the increase in the AMP:ATP ratio and the activa-
tion of AMPK that occurs during lipolysis. A similar hypothesis
has been proposed, but not tested, by others, based on studies in
which intracellular fatty acidswere increased in adipocytes dur-
ing lipolysis (57), in muscle treated with isoprenaline (58), and
in hepatocytes incubated with exogenous FFAs (59).
These results do not exclude the possibility that other events
could contribute to the decrease in energy state that accompa-
nies lipolysis. One of these could be the uncoupling of oxidative
phosphorylation, a phenomenon that has been observed in iso-
lated rat adipocytes stimulated with lipolytic hormones (50, 56)
and is in keeping with the intrinsic uncoupling effects of FFAs
on mitochondria (60). Another is the energy consumed by the
formation of glycerol 3-phosphate used for reesterification of
FFAs. In keeping with this possibility, glycerol 3-phosphate for-
mation from glucose (56, 61, 62) and from pyruvate and lactate
(glyceroneogenesis) (55) has been shown to increase in adipo-
cytes during lipolysis. Hypothetically, glucose or FFA catabo-
lism could be impaired during lipolysis. However, previous
studies have shown that various lipolytic hormones increase
glucose oxidation and lactate production and, if anything, that
would increase cellular ATP levels (61–64). Also, fatty acid oxi-
dation has been reported to account for only a very small por-
tion of oxygen consumption andATP production in adipocytes
(51). It is noteworthy that in the experiments presented here,
triacsin C did not completely eliminate the isoproterenol-in-
duced decrease in cellular energy state. Apart from the above-
mentioned possibilities, this could also be due to a lack of effect
of triacsin C on certain ACS isoforms (65).
Another novel finding was that inhibition of AMPK activity
by compound C under base-line conditions led to increases in
bothROSproduction and lipolysis (Fig. 7,A andC). In addition,
we observed a 25% increase in ROS generation when lipolysis
was stimulated with isoproterenol (no compound C) (Fig. 7B)
or other lipolytic agents.3 Most impressively, the effect of iso-
proterenol was magnified 5-fold in the presence of compound
C. Enhanced ROS production has been found previously in
3T3-L1 adipocytes incubated with exogenous saturated or
unsaturated FFAs (45), an effect attributed to an up-regulation
ofNAD(P)Hoxidase activity (44). Likewise, increasedROSpro-
duction has been demonstrated in white adipose tissue of an
obese insulin-resistant rodent, the KKAy mice (44). Our data
suggest the following: 1) that an increase in endogenous FFA
availability augments ROS generation, and 2) that AMPK acti-
vation during lipolysis probably limits this oxidative stress.
Studies in which AMPK activity in the adipocyte is down-reg-
ulated by genetic means are needed to confirm this conclusion;
however, it is noteworthy that a similar effect of AMPK activa-
tion on ROS generation has been observed in human endothe-
lial cells incubated with linoleate or palmitate (10, 46) and in
neutrophils treatedwith phorbolmyristate acetate (12). In both
situations, AMPK activation was shown to diminish NAD(P)H
oxidase activity. Enhanced ROS production has been found to
have several detrimental effects on adipocyte function, includ-
ing insulin resistance (66, 67), enhanced expression and release
of pro-inflammatory cytokines (44, 45, 66–68), and increased
apoptosis (69). Whether a failure to activate AMPK during
lipolysis contributes to such changes remains to be determined.
A second effect of AMPK inhibition by compound C was to
decrease cellular energy state under both basal and isoprotere-
nol-stimulated conditions (Fig. 8). To our knowledge, this study
provides the first evidence that in the adipocyte AMPK pre-
serves ATP under base-line conditions and, perhaps more
importantly, when the stimulation of lipolysis causes energy
depletion. As already noted, AMPK acts acutely in energy-
3 M.-S. Gauthier and N. B. Ruderman, unpublished data.
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stressed cells to stimulate processes that generate ATP (glucose
transport and fatty acid oxidation) and to down-regulate ATP-
consuming pathways that are not acutely needed for cell sur-
vival (fatty acid, triglyceride and protein synthesis, as well as
gluconeogenesis) (7). This concept has been well illustrated in
muscle and liver; however, its applicability to the adipocyte has
been less explored (70). Some reports suggest that AMPK
inhibits lipid (71–73) and protein synthesis (74) in adipocytes as
it does in other cells. Its effects on glucose transport and fatty acid
oxidation in the adipocyte are less clear (72, 75–77). Another
means by which AMPK could restrain energy depletion in adipo-
cytes is by reducing lipolysis. In keeping with this notion, most
studies suggest that AMPK acts as an anti-lipolytic signal (33, 70,
71, 74, 78, 79), possibly by phosphorylating and inhibiting hor-
mone-sensitive lipase (70), although others have found it is pro-
lipolytic (24, 29) ormaynot alter lipolysis (73, 79). In this study, the
inhibition of AMPK by compound C induced a 30% increase in
lipolysis over 20 h under base-line conditions but did not affect its
stimulation by isoproterenol (Fig. 7C). The reason for this differ-
ence is unclear. The possibility that compound C might exert
effects that are independent of AMPK inhibition needs to be con-
sidered, and for this, studies in which AMPK activity is down-
regulated by genetic means will be required.
Although, if anything, AMPK appears to inhibit lipolysis in
the adipocyte, during exercise and stimulation by agents that
increase cAMP, both AMPK activity and lipolysis are concur-
rently enhanced. We would propose that, in these settings,
rather than preventing lipolysis, AMPK acts to restrain it to
protect the fat cell from further energy depletion. If correct,
AMPK would not be acting as a simple on and off switch but as
a rheostat that controls the lipolytic rate. An analogous situa-
tion also occurs during exercise in the liver when both AMPK
activity and gluconeogenesis, an energy-requiring process that
can occur at a high rate, are simultaneously enhanced despite
the fact that AMPK has been shown to inhibit both key glu-
coneogenic enzymes and hepatic glucose production (80).
In conclusion, the activation of AMPK in adipocytes by
agents that increase cAMP appears to be secondary to an
increase in the AMP:ATP ratio that accompanies lipolysis and
not the direct result of increases in cAMP levels and PKA activ-
ity. This decrease in energy state appears to be due, at least in
part, to the acylation of the fatty acids released during lipolysis.
The data also suggest that AMPK activation may restrain
energy depletion and ROS production that occur during the
stimulation of lipolysis. Studies in which AMPK is genetically
knocked down are needed to confirm this role.
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